Trex Wind-down (OTCPK:TMBR.Q) - Stock Price, News & Analysis

TMBR.Q Stock Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases.

About the company

TMBR.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Highly volatile share price over the past 3 months

Earnings have declined by 16.6% per year over past 5 years

+ 3 more risks

Trex Wind-down, Inc. Competitors

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Halo Collective

OTCPK:HCAN.F

US$150.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

Price History & Performance

Summary of all time highs, changes and price drops for Trex Wind-down
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$3.36
52 Week Low	US$0.0001
Beta	-1.6
1 Month Change	-50.00%
3 Month Change	-91.67%
1 Year Change	-99.99%
3 Year Change	-100.00%
5 Year Change	n/a
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	TMBR.Q	US Pharmaceuticals	US Market
7D	0%	-3.1%	-1.7%
1Y	-100.0%	11.5%	22.4%

Return vs Industry: TMBR.Q underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.

Return vs Market: TMBR.Q underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is TMBR.Q's price volatile compared to industry and market?
TMBR.Q volatility
TMBR.Q Average Weekly Movement	119.8%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: TMBR.Q's share price has been volatile over the past 3 months.

Volatility Over Time: TMBR.Q's weekly volatility has decreased from 647% to 120% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2019	9	John Koconis	www.timberpharma.com

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea.

Trex Wind-down, Inc. Fundamentals Summary

How do Trex Wind-down's earnings and revenue compare to its market cap?
TMBR.Q fundamental statistics
Market cap	US$308.00
Earnings (TTM)	-US$14.93m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is TMBR.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TMBR.Q income statement (TTM)
Revenue	US$0
Cost of Revenue	US$8.73m
Gross Profit	-US$8.73m
Other Expenses	US$6.21m
Earnings	-US$14.93m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.84
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did TMBR.Q perform over the long term?

See historical performance and comparison

TMBR.Q Stock Overview

Rewards

Risk Analysis

Trex Wind-down, Inc. Competitors

OTCPK:RVLP.Q

US$111.0

OTCPK:HCAN.F

US$150.0

OTCPK:PLXP.Q

US$30.0

OTCPK:CWWB.F

US$27.0

Price History & Performance

Recent News & Updates

Timber Pharmaceuticals, Inc. Presents Preliminary Results from the ASCEND Trial in A Late-Breaking Session At the 2024 American Academy of Dermatology (AAD) Annual Meeting

Timber Pharmaceuticals Receives Written Notice from the Staff of NYSE Regulation

Timber Pharmaceuticals, Inc.(NYSEAM:TMBR) dropped from S&P TMI Index

Timber Pharmaceuticals, Inc. Filed for Bankruptcy

Timber Pharmaceuticals, Inc. announced delayed 10-Q filing

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

Recent updates

Timber Pharmaceuticals, Inc. Presents Preliminary Results from the ASCEND Trial in A Late-Breaking Session At the 2024 American Academy of Dermatology (AAD) Annual Meeting

Timber Pharmaceuticals Receives Written Notice from the Staff of NYSE Regulation

Timber Pharmaceuticals, Inc.(NYSEAM:TMBR) dropped from S&P TMI Index

Timber Pharmaceuticals, Inc. Filed for Bankruptcy

Timber Pharmaceuticals, Inc. announced delayed 10-Q filing

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

LEO Pharma A/S entered into a definitive agreement to acquire Timber Pharmaceuticals, Inc. (NYSEAM:TMBR) for $8.1 million.

Timber Pharmaceuticals Discloses Communication from NYSE American

Timber Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$4.15 loss in 3Q 2021)

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc. announced that it has received funding

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.082 loss in 2Q 2021)

Timber Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Timber Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Timber Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 3 Ascend Clinical Trial Evaluating Tmb-001 in Congenital Ichthyosis

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.054 loss in 1Q 2021)

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2022

Full year 2021 earnings released: US$0.27 loss per share (vs US$0.97 loss in FY 2020)

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis

High number of new and inexperienced directors

Timber Pharmaceuticals, Inc. Provides Update of Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2B Control Study Evaluating TMB-001 in Congenital Ichthyosis

First quarter 2021 earnings released: US$0.054 loss per share (vs US$0.30 loss in 1Q 2020)

Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001

Executive Chairman of the Board Michael Derby has left the company

Full year 2020 earnings released: US$0.97 loss per share

Timber Pharmaceuticals Announces 50% Enrollment in Phase 2B Control Study in Congenital Ichthyosis

New 90-day high: US$3.44

New 90-day high: US$1.47

Timber Pharmaceuticals, Inc. Announces Management Changes

Timber Pharmaceuticals, Inc. Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis

New 90-day low: US$0.89

Timber Pharmaceuticals, Inc. announced delayed 10-Q filing

Timber Pharmaceuticals LLC completed the acquisition of BioPharmX Corporation (AMEX:BPMX) in a reverse merger transaction.

Shareholder Returns

Price Volatility

About the Company

Trex Wind-down, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue